MPN Research Foundation

Representing the over 300,000 patients in the U.S. (and countless more across the world) who suffer from Myeloproliferative neoplasms (MPNs), the MPN Research Foundation MPNRF) invests its energy and funds into cutting-edge MPN science. We are proud that since 1999 our patient-led organization has “provided key support for virtually every major advance that has been made in the MPNs since 2000”.

Myeloproliferative neoplasms (MPNs) are a closely related group of progressive blood cancers in which the bone marrow typically overproduces one of the mature blood elements such as platelets or red cells. Other shared features of the MPNs include tendencies toward blood clotting/bleeding, organ enlargement, and bone marrow scarring (fibrosis). Patients suffer from a host of symptoms ranging from mild (e.g., fatigue, itching) to life-threatening (e.g., strokes, blood clots, and heart attacks), and the diseases progress over time, sometimes to acute leukemia. At end-stage, MPN patients are no longer able to make blood, a common cause of death in MPN patients.